Alvotech Gears Up For Public Listing With Fresh Leadership
Tanya Zharov Joins Biosimilars Firm As Deputy CEO In Iceland
Alvotech has brought in public markets specialist Tanya Zharov as deputy CEO for the firm in Iceland, as it prepares for a public listing.
You may also be interested in...
Alvotech ended 2021 by revealing major plans for a SPAC merger that will provide fresh impetus for the biosimilars specialist with an injection of almost $500m in funding. In the first part of an exclusive two-part interview, founder and chairman Robert Wessman tells Generics Bulletin how the firm plans to move forward following the transaction.
Eight years after its inception, pure-play biosimilars company Alvotech has announced plans to list on the NASDAQ via a SPAC merger that will deliver hundreds of millions in cash to fund product development and future growth.
Icelandic biosimilars specialist Alvotech has eased some of its liability to bondholders following a debt-to-equity conversion, at the same time as it improved terms and extended its maturity.